Jazz Pharmaceuticals plc, of Dublin, reported results at the SLEEP meeting in Denver from a human abuse liability study of JZP-110, an investigational wake-promoting agent in phase III development for the treatment of excessive sleepiness in adult patients with narcolepsy or with obstructive sleep apnea.